The American Society of Clinical Oncology (ASCO)31 has recommended that SLN biopsy can be omitted for clinically node-negative women aged ≥70 with early-stage invasive breast cancer, that is HER2-negative and hormone receptor-positive. Here, ERBB2 is linked to invasive breast carcinoma.